Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer is grown by anodizing at a voltage between 50 and 150 V, and the biocidal material incorporated in it by ion exchange. This produces a significantly harder surface than anodizing at low voltage, and generates pits containing ion-absorbing material.

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer may be grown from the metal substrate, by anodizing, and the biocidal material incorporated in it by ion exchange. Alternatively the layer may be deposited by electroplating, followed by diffusion bonding so as to become integral with the metal substrate. In either case, silver is a suitable biocidal material; and both the release rate and the quantity of biocidal material should be low to avoid toxic effects on body cells. Electropolishing the surface before formation of the surface layer is also beneficial, and this may be achieved by electropolishing.

Abstract: Metal implants (10) are treated by anodising the surface (11, 12) in contact with an electrolyte, and then briefly subjecting the anodised surface to a reversed voltage. During a first anodising stage the surfaces are passivated, while during a subsequent anodising stage pits are formed in the passivating surface layer. Rough portions (15) of the surface, in particular portions produced by plasma spraying of metal powder, are sealed with a watertight cover (20) during at least part of the anodising process. After rinsing, biocidal metal ions are subsequently absorbed into the surface of the implant. This provides the implant with biocidal properties. The use of the cover (20) enables a more uniform geometric distribution of biocidal metal ions to be achieved.

Abstract: Metal objects are treated by anodising the metal object in contact with an acidic solution, and then subjecting the anodised metal object to a reversed voltage (compared to the anodising voltage). The thus-treated metal object is then contacted with a biocidal metal-containing solution. Biocidal metal is deposited on the surface of the metal object, resulting in improved biocidal properties.

Abstract: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.

Abstract: Predictive popular content replication is described. In an embodiment service node(s) can provide media content when requested by client devices. Previous requests for the media content can be trended to forecast its popularity prior to receiving additional requests for the media content. Replication of the media content can then be initiated such that the media content is available and can be rapidly accessed to serve the additional requests for the media content. The media content can be replicated into cache memory for faster access than from disk-based media to serve the additional requests for the media content.

Abstract: A fabricating process for a multi-layer printed circuit board containing embedded passive components is provided. The method includes a calibration step wherein a calibration measurement is taken of the geometry or at least one electrical parameter of an arrangement of calibration test points for a circuit forming process, such as masking, etching and/or lamination. A process control step is performed during the process, wherein a process control measurement is taken of at least one electrical parameter at one or more process control test points along one or more axes outside areas in which a circuit is to be formed. An analysis is performed of at least the calibration measurement and the process control measurement to calculate a CAD geometry change required to improve precision of embedded passive components to be printed on the multi-layer printed circuit board.

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.

Abstract: In a process for anodising a metal object (12), the metal object (12) is contacted with an anodising electrolyte (32), and is first pre-anodised so as to grow a thin oxide film on the surface. The microscopic surface area is then deduced from electrical measurements either during pre-anodising or on the pre-anodised surface. The metal object (12) can then be anodised. This is applicable when treating an implant to provide a surface that has the ability to incorporate biocidal material such as silver ions. The pre-anodising uses a low voltage, for example no more than 2. V, and may take less than 120 seconds.

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: A process is provided for recovering methane from landfill feed gas and other anaerobic digestors. The process comprising the following steps: firstly treating the feed gas to remove H2S; subsequently compressing the gas; and then treating the gas to remove further impurities. Additionally, there is provided a chiller for reducing the temperature of a gas flow. The chiller comprising: a shell arranged to be chilled, a plurality of bores through the shell and through which the gas flows, in use, and forming, together with the shell, a heat exchanger, a tangential inlet to each bore for creating a spiral flow of the gas through the bore, in use. Furthermore, a process is provided for purifying a gas feed using a reversible gas absorber unit comprising two hollow fiber gas/liquid contactors, each of which is arranged to provide a counter-current flow.

Abstract: Metal implants (10) are treated by anodising the surface (11, 12) in contact with an electrolyte, and then briefly subjecting the anodised surface to a reversed voltage. During a first anodising stage the surfaces are passivated, while during a subsequent anodising stage pits are formed in the passivating surface layer. Rough portions (15) of the surface, in particular portions produced by plasma spraying of metal powder, are sealed with a watertight cover (20) during at least part of the anodising process. After rinsing, biocidal metal ions are subsequently absorbed into the surface of the implant. This provides the implant with biocidal properties. The use of the cover (20) enables a more uniform geometric distribution of biocidal metal ions to be achieved.

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; R1 is hydrogen, halo, hydroxy, C1-4 alkyl, or C1-4 alkoxy; R2 is C3-4 alkyl, or C3-6cycloalkyl; R3 is hydrogen or C1-3 alkyl: R4 is S(O)2R6 or C(O)R7; R5 is hydrogen, C1-3alkyl, C2-3 alkyl substituted with —OH or C1-3 alkoxy, or —CH2-pyrydyl; R6 is C1-3 alkyl; or R5 and R6 taken together from C3-4 alkylenyl; and R7 is hydrogen, C1-3alkyl, or pyrydyl; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof.

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: Adaptive content load balancing is described. In an embodiment, client requests for media content are received and service node(s) are determined that can provide the requested media content to a client. Each client request is registered to correlate client sessions with requested media content provided from a service node, and a determination is made as to whether to replicate the requested media content for each received client request to optimize session capacity over the service node(s).

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: A metal object is treated to form an integral surface layer by: (a) immersing the metal object in an anodising electrolyte, and passivating the metal to form an anodised layer on the metal object; (b) continuing the application of a potential to modify the surface layer; (c) then treating the metal object with a chemical reducing agent so a hydrous metal oxide is formed; and (d) then contacting the metal object with a solution containing a biocidal material so as to incorporate biocidal material into the surface layer.

Abstract: Metal objects are treated by anodising (P, SE) the metal object in contact with an acidic solution, and then subjecting the anodised metal object to a reversed voltage (VR). The anodising is performed in two stages, firstly to passivate (P) with the formation of a surface layer, and secondly to form pits in this surface layer (SE). The second stage (SE) of anodising is performed at a lower voltage than the first stage (P). After the reversed voltage step (VR) the metal object is then contacted with a biocidal metal-containing solution. Biocidal metal is absorbed into the surface of the metal object, resulting in improved biocidal properties. The lower voltage of the second stage anodising (SE) results in reduced processing time.